TY - JOUR
T1 - Symptoms COVID 19 Positive Vapers Compared to COVID 19 Positive Non-vapers
AU - McFadden, David D.
AU - Bornstein, Shari L.
AU - Vassallo, Robert
AU - Salonen, Bradley R.
AU - Bhuiyan, Mohammed Nadir
AU - Schroeder, Darrell R.
AU - Croghan, Ivana T.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported in part by Mayo Clinic Department of Medicine, General Internal Medicine. The data entry system used was RedCap, which is supported in part by the Center for Clinical and Translational Science award (UL1TR002377) from the National Center for Advancing Translational Sciences (NCATS).
Publisher Copyright:
© The Author(s) 2022.
PY - 2022/1
Y1 - 2022/1
N2 - Objectives: The purpose of the present study was to assess and describe the severity of symptoms reported by Covid-19 positive patients who vaped (smoked e-cigarettes) when compared to those who did not vape or smoke at the time of the diagnosis of Covid-19. Methods: Patients from this study are from a well-characterized patient cohort collected at Mayo Clinic between March 1, 2020 and February 28, 2021; with confirmed COVID-19 diagnosis defined as a positive result on reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays from nasopharyngeal swab specimens. Among the 1734 eligible patients, 289 patients reported current vaping. The cohort of vapers (N = 289) was age and gender matched to 1445 covid-19 positive patients who did not vape. The data analyzed included: date of birth, gender, ethnicity, race, marital status, as well as lifestyle history such as vaping and smoking and reported covid-19 symptoms experienced. Results: A logistic regression analysis was performed separately for each symptom using generalized estimating equations (GEE) with robust variance estimates in order to account for the 1:5 age, sex, and race matched set study design. Patients who vaped and developed Covid-19 infection were more likely to have chest pain or tightness (16% vs 10%, vapers vs non vapers, P =.005), chills (25% vs 19%, vapers vs non vapers, P =.0016), myalgia (39% vs 32%, vapers vs non vapers, P =.004), headaches (49% vs 41% vapers vs non vapers, P =.026), anosmia/dysgeusia (37% vs 30%, vapers vs non vapers, P =.009), nausea/vomiting/abdominal pain (16% vs 10%, vapers vs non vapers, P =.003), diarrhea (16% vs 10%, vapers vs non vapers, P =.004), and non-severe light-headedness (16% vs 9%, vapers vs non vapers, P <.001). Conclusion: Vapers experience higher frequency of covid-19 related symptoms when compared with age and gender matched non-vapers. Further work should examine the impact vaping has on post-covid symptom experience.
AB - Objectives: The purpose of the present study was to assess and describe the severity of symptoms reported by Covid-19 positive patients who vaped (smoked e-cigarettes) when compared to those who did not vape or smoke at the time of the diagnosis of Covid-19. Methods: Patients from this study are from a well-characterized patient cohort collected at Mayo Clinic between March 1, 2020 and February 28, 2021; with confirmed COVID-19 diagnosis defined as a positive result on reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays from nasopharyngeal swab specimens. Among the 1734 eligible patients, 289 patients reported current vaping. The cohort of vapers (N = 289) was age and gender matched to 1445 covid-19 positive patients who did not vape. The data analyzed included: date of birth, gender, ethnicity, race, marital status, as well as lifestyle history such as vaping and smoking and reported covid-19 symptoms experienced. Results: A logistic regression analysis was performed separately for each symptom using generalized estimating equations (GEE) with robust variance estimates in order to account for the 1:5 age, sex, and race matched set study design. Patients who vaped and developed Covid-19 infection were more likely to have chest pain or tightness (16% vs 10%, vapers vs non vapers, P =.005), chills (25% vs 19%, vapers vs non vapers, P =.0016), myalgia (39% vs 32%, vapers vs non vapers, P =.004), headaches (49% vs 41% vapers vs non vapers, P =.026), anosmia/dysgeusia (37% vs 30%, vapers vs non vapers, P =.009), nausea/vomiting/abdominal pain (16% vs 10%, vapers vs non vapers, P =.003), diarrhea (16% vs 10%, vapers vs non vapers, P =.004), and non-severe light-headedness (16% vs 9%, vapers vs non vapers, P <.001). Conclusion: Vapers experience higher frequency of covid-19 related symptoms when compared with age and gender matched non-vapers. Further work should examine the impact vaping has on post-covid symptom experience.
KW - covid-19
KW - e-cigarettes
KW - vaping
UR - http://www.scopus.com/inward/record.url?scp=85122377881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122377881&partnerID=8YFLogxK
U2 - 10.1177/21501319211062672
DO - 10.1177/21501319211062672
M3 - Article
C2 - 34986700
AN - SCOPUS:85122377881
SN - 2150-1319
VL - 13
JO - Journal of primary care & community health
JF - Journal of primary care & community health
ER -